Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lifecore Biomedical (LFCR) Operating Expenses: 2009-2025

Historic Operating Expenses for Lifecore Biomedical (LFCR) over the last 17 years, with May 2025 value amounting to $50.6 million.

  • Lifecore Biomedical's Operating Expenses fell 26.71% to $11.1 million in Q2 2025 from the same period last year, while for May 2025 it was $53.1 million, marking a year-over-year increase of 4.79%. This contributed to the annual value of $50.6 million for FY2025, which is 0.27% down from last year.
  • As of FY2025, Lifecore Biomedical's Operating Expenses stood at $50.6 million, which was down 0.27% from $50.7 million recorded in FY2024.
  • Over the past 5 years, Lifecore Biomedical's Operating Expenses peaked at $50.9 million during FY2022, and registered a low of $47.8 million during FY2021.
  • In the last 3 years, Lifecore Biomedical's Operating Expenses had a median value of $50.6 million in 2025 and averaged $50.3 million.
  • As far as peak fluctuations go, Lifecore Biomedical's Operating Expenses fell by 26.82% in 2021, and later increased by 6.48% in 2022.
  • Over the past 5 years, Lifecore Biomedical's Operating Expenses (MRY) stood at $47.8 million in 2021, then grew by 6.48% to $50.9 million in 2022, then fell by 2.12% to $49.8 million in 2023, then rose by 1.83% to $50.7 million in 2024, then decreased by 0.27% to $50.6 million in 2025.
  • Its Operating Expenses was $50.6 million in FY2025, compared to $50.7 million in FY2024 and $49.8 million in FY2023.